Caption Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Caption Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.29M	Sell	130,000 -90,000	-41%	-$1.98M	0.02%	726
2026 Q1	$4.9M	Buy	220,000 +200,000	+1,000%	+$4.78M	0.03%	539
2025 Q4	$534K	Sell	20,000 -156,300	-89%	-$3.74M	﹤0.01%	1231
2025 Q3	$3.76M	Buy	176,300 +146,300	+488%	+$3.46M	0.03%	594
2025 Q2	$647K	Buy	30,000 +10,000	+50%	+$186K	0.01%	1051
2025 Q1	$332K	Buy	+20,000	New	+$363K	﹤0.01%	1181
2024 Q4	–	Sell	-60,000	Closed	-$923K	–	1422
2024 Q3	$923K	Buy	60,000 +30,000	+100%	+$500K	0.01%	803
2024 Q2	$488K	Sell	30,000 -153,400	-84%	-$2.48M	0.01%	815
2024 Q1	$3.39M	Buy	+183,400	New	+$4.54M	0.05%	397
2023 Q4	–	Sell	-72,500	Closed	-$1.51M	–	1294
2023 Q3	$1.51M	Buy	72,500 +45,000	+164%	+$1.22M	0.02%	652
2023 Q2	$659K	Buy	+27,500	New	+$611K	0.01%	759
2022 Q4	–	Sell	-45,000	Closed	-$738K	–	1234
2022 Q3	$738K	Sell	45,000 -20,000	-31%	-$324K	0.01%	969
2022 Q2	$916K	Sell	65,000 -18,700	-22%	-$349K	0.01%	906
2022 Q1	$2.03M	Sell	83,700 -35,000	-29%	-$847K	0.02%	751
2021 Q4	$2.77M	Buy	+118,700	New	+$2.39M	0.03%	670
2021 Q2	–	Sell	-251,000	Closed	-$6.47M	–	1251
2021 Q1	$6.47M	Buy	251,000 +165,800	+195%	+$7.3M	0.14%	186
2020 Q4	$4.56M	Buy	85,200 +30,000	+54%	+$1.49M	0.1%	248
2020 Q3	$2.28M	Hold	55,200	–	–	0.05%	393
2020 Q2	$2.67M	Buy	+55,200	New	+$2.65M	0.09%	308
2020 Q1	–	Sell	-80,000	Closed	-$3.42M	–	825
2019 Q4	$3.42M	Buy	80,000 +20,000	+33%	+$870K	0.12%	247
2019 Q3	$2.16M	Sell	60,000 -67,900	-53%	-$2.06M	0.11%	224
2019 Q2	$3.42M	Buy	127,900 +92,900	+265%	+$2.37M	0.17%	170
2019 Q1	$940K	Buy	+35,000	New	+$817K	0.05%	366

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Caption Management's ACAD Position: Q2 2026 in Review

Caption Management reduced its Acadia Pharmaceuticals (ACAD) stake by 93% in Q2 2026, selling an estimated $2.47M and leaving 8,419 shares worth $213K. The position accounts for ﹤0.01% of the portfolio, ranked #1460.

Caption Management first reported a position in ACAD in Q2 2018 and has held it in 17 quarters since. The position peaked at $3.24M in Q4 2020. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Caption Management held 8,419 shares of Acadia Pharmaceuticals worth $213K as of Q2 2026.
Caption Management sold 112,458 Acadia Pharmaceuticals shares in Q2 2026, an estimated $2.47M.
Acadia Pharmaceuticals made up ﹤0.01% of Caption Management's portfolio in Q2 2026, its #1460 holding.
Caption Management first reported a position in Acadia Pharmaceuticals in Q2 2018 and has held it in 17 quarters since.
Caption Management's Acadia Pharmaceuticals position peaked at $3.24M in Q4 2020.
353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.